Abstract
Endometriosis is a chronic, in -
flammatory, estrogen-dependent gyneco -
logical disease that affects approximately
10% of women of reproductive age and is
a major cause of chronic pelvic pain, infer-
tility, and reduced quality of life. Althou -
gh conventional treatments are based pri -
marily on hormonal therapies and surgical
approaches, many cases present with symp-
tom recurrence or therapeutic limitations.
Recently, glucagon-like peptide-1 (GLP-
1) and glucose-dependent insulinotropic
polypeptide (GIP) receptor agonists—wi -
dely used in the treatment of obesity and
type 2 diabetes mellitus—have attracted
interest due to their anti-inflammatory,
immunomodulatory, and metabolic effects.
The present study aims to discuss the poten-
tial mechanisms by which GLP-1 and GIP
agonists may represent a new therapeutic
strategy for endometriosis. This is a narra-
tive review of the literature based on recent
publications regarding the pathophysiology
of endometriosis, systemic inflammation,
insulin resistance, obesity, and the actions
of incretin mimetics. The findings suggest
that these medications may help reduce
the inflammatory process, modulate the
immune response, control metabolism,
and slow the progression of endometriotic
lesions. Although clinical evidence is still
limited, preliminary results point to a pro-
mising area of research that could expand
the therapeutic options available to patients
with endometriosis.
Keywords
Endometriosis; GLP-1; GIP;
Tirzepatide; Semaglutide; Inflammation;
Women’s Health.
Introduction
Endometriosis is a chronic inflamma-
tory condition characterized by the pre -
sence of endometrium-like tissue outside
the uterine cavity, primarily affecting the
ovaries, pelvic peritoneum, and uterosacral
ligaments. It is estimated that the disease
affects approximately 190 million women
worldwide, representing a significant pu -
blic health problem.
Despite its high prevalence, the pa -
thophysiology of endometriosis remains
complex and multifactorial, involving
hormonal, genetic, immunological, and
inflammatory changes. The peritoneal en-
vironment of patients exhibits increased
production of pro-inflammatory cytokines,
angiogenic factors, and pain mediators,
which promote the survival and prolifera-
tion of endometriotic implants.
In recent decades, numerous studies
have demonstrated the close relationship
between systemic inflammation, energy
metabolism, and gynecological diseases. At
the same time, the development of GLP-
1 receptor agonists and dual GLP-1/GIP
agonists has revolutionized the treatment
of obesity and type 2 diabetes mellitus,
showing benefits that extend beyond glyce-
mic control.
In addition to significant weight loss,
medications such as semaglutide, liragluti-
de, and tirzepatide exhibit anti-inflamma-
tory, antioxidant, and immunomodulatory
properties, sparking interest in their applica-
tion for chronic inflammatory conditions.
In this context, the hypothesis arises that
such agents may also exert beneficial effects
on the pathophysiology of endometriosis.
DOI https:/ /doi.org/10.22533/at.ed.51572172608095
Article 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS
3
Objective
T o analyze the available scientific evi-
dence on the potential benefits of GLP-1
receptor agonists and dual GLP-1/GIP
agonists in the treatment of endometriosis,
discussing their pathophysiological mecha-
nisms and future therapeutic prospects.
METHODOLOGY
This is a narrative literature review.
We searched for publications indexed in
the PubMed, Scopus, Web of Science, and
Virtual Health Library (BVS) databases,
using the following search terms in English
and Portuguese: “Endometriosis,” “GLP-
1 receptor agonists,” “GIP ,” “Tirzepatide,”
“Semaglutide,” “Inflammation,” “Obesity,”
“Metabolic Dysfunction,” and “Women’s
Health.”
Original articles, systematic reviews,
meta-analyses, and experimental studies pu-
blished between 2015 and 2025 were inclu-
ded. The selection prioritized studies related
to the inflammatory pathophysiology of
endometriosis, the mechanisms of action of
GLP-1 and GIP agonists, and the potential
applications of these drugs in inflammatory
and gynecological diseases.
Following a critical analysis of the lite-
rature, the data were organized into thema-
tic categories to discuss the main mechanis-
ms involved.
Discussion
Endometriosis as a Systemic
Inflammatory Disease
The contemporary view of endome -
triosis goes beyond the concept of an exclu-
sively gynecological disease. It is now recog-
nized that the condition involves a persistent
systemic inflammatory state, characterized
by elevated levels of pro-inflammatory cy -
tokines such as TNF- α, IL-1 β, IL-6, and
IL-8.
These mediators promote angiogene-
sis, cell proliferation, and neuronal sensiti-
zation, contributing to chronic pain and the
progression of lesions. Furthermore, immu-
nological alterations facilitate evasion of
cellular surveillance mechanisms, allowing
ectopic implants to persist.
This inflammatory scenario represents
a potential therapeutic target for new phar-
macological approaches.
The Relationship Between
Metabolism, Obesity, and
Endometriosis
Although endometriosis has traditio -
nally been associated with women with a
lower body mass index, recent studies de -
monstrate a complex interaction between
energy metabolism, insulin resistance, and
inflammation.
Obesity promotes increased produc -
tion of inflammatory adipokines, including
leptin and resistin, as well as reduced adi -
ponectin levels, thereby fostering a syste -
mic pro-inflammatory state. These factors
may exacerbate pain, fatigue, and disease
progression.
DOI https:/ /doi.org/10.22533/at.ed.51572172608095
Article 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS
4
Additionally, metabolic changes can
directly influence the activity of macropha-
ges and immune cells present in the perito-
neal microenvironment, contributing to the
maintenance of chronic inflammation.
Mechanisms of Action of GLP-1
Agonists
GLP-1 is an incretin hormone pro -
duced by intestinal L cells in response to
food intake. Its agonists promote increased
insulin secretion, reduced glucagon levels,
delayed gastric emptying, and increased
satiety.
However, recent studies show that the
benefits of these medications extend beyond
metabolic control. Several studies have
identified anti-inflammatory properties as-
sociated with reduced expression of TNF-α,
IL-6, and C-reactive protein.
Furthermore, GLP-1 agonists appe -
ar to modulate macrophage activity, redu -
cing polarization toward pro-inflammatory
phenotypes and promoting a less aggressive
immune environment.
These mechanisms may be particularly
relevant in endometriosis, whose progres -
sion depends on the maintenance of a per-
sistent inflammatory state.
The Potential of Dual GLP-1/GIP
Agonists
Tirzepatide, the first dual GLP-1/GIP
agonist approved for the treatment of obesi-
ty and type 2 diabetes, demonstrates supe-
rior results in reducing body weight and im-
proving metabolic markers when compared
to standalone GLP-1 agonists.
GIP also performs important immu -
nometabolic functions, influencing the re-
gulation of inflammation and energy me -
tabolism. Experimental studies suggest that
the combined activation of GLP-1 and GIP
receptors may potentiate systemic anti-in -
flammatory effects.
Although there are still no robust cli-
nical trials directly evaluating tirzepatide in
patients with endometriosis, the observed
biological mechanisms suggest a potential
benefit in reducing the disease’s inflamma-
tory activity.
Impact on Pain and Quality of Life
Chronic pelvic pain is the main symp-
tom of endometriosis and is closely linked
to neuroinflammation. Recent evidence
shows that GLP-1 agonists may exert neu-
roprotective and pain-modulating effects by
reducing inflammatory mediators and oxi-
dative stress.
In addition, the significant weight
loss observed with these medications may
improve physical and psychological aspects
that are often compromised in women with
endometriosis, including fatigue, self-este -
em, sleep quality, and mental health.
Therefore, the potential benefits of
these drugs may extend beyond the reduc-
tion of lesions to encompass an overall im-
provement in quality of life.
Current Limitations of the Evidence
Despite growing scientific interest, the
use of GLP-1 and GIP agonists in endome-
triosis is still in the early stages of research.
Much of the available evidence derives from
experimental studies, animal models, and
pathophysiological extrapolations.
DOI https:/ /doi.org/10.22533/at.ed.51572172608095
Article 5 GLP-1 AND GIP AGONISTS: A NEW THERAPEUTIC APPROACH FOR ENDOMETRIOSIS
5
There is a lack of randomized clinical
trials that directly evaluate outcomes such as
pain reduction, lesion regression, impact on
fertility, and improvement in quality of life
in patients with endometriosis.
Thus, although the results are promi-
sing, it is not yet possible to routinely re -
commend these therapies for the treatment
of the disease outside of research protocols
or approved indications for obesity and
diabetes.
Conclusion
Endometriosis is a complex inflamma-
tory disease that continues to pose a signifi-
cant therapeutic challenge. GLP-1 receptor
agonists and dual GLP-1/GIP agonists are
emerging as potential therapeutic alternati-
ves due to their anti-inflammatory, immu-
nomodulatory, metabolic, and neuroprotec-
tive effects.
The pathophysiological mechanisms
involved suggest that these medications
may act on multiple aspects of the disease,
including reducing systemic inflammation,
modulating the immune system, improving
energy metabolism, and potentially allevia-
ting chronic pain.
Although the current evidence is still
preliminary, the growing number of studies
points to a new and promising line of resear-
ch in the treatment of endometriosis. Future
clinical trials will be essential to determine
the efficacy, safety, and applicability of these
agents in gynecological practice.
References
Agarwal SK, Chapron C, Giudice LC, et al.
Clinical diagnosis of endometriosis: a call to
action. American Journal of Obstetrics and
Gynecology. 2019;220(4):354.e1-354.e12.
Bulun SE. Endometriosis. New England Jour-
nal of Medicine. 2009;360(3):268-279.
Chapron C, Marcellin L, Borghese B, Santulli
P . Rethinking mechanisms, diagnosis and ma-
nagement of endometriosis. Nature Reviews
Endocrinology. 2019;15(11):666-682.
Giudice LC. Endometriosis. New England
Journal of Medicine. 2010;362(25):2389-2398.
Kakoly NS, Moran LJ, Teede HJ, Joham AE.
Cardiometabolic risks in women with en -
dometriosis. Human Reproduction Update.
2018;24(5):553-568.
Muller TD, Finan B, Bloom SR, et al. Gluca -
gon-like peptide 1 (GLP-1). Molecular Meta-
bolism. 2019;30:72-130.
Nanda S, Jain A, Marwah N. Anti-inflamma-
tory effects of GLP-1 receptor agonists: current
evidence and future directions. Diabetes Re -
search and Clinical Practice. 2023;198:110609.
Surrey E, Taylor HS, Giudice LC, et al. Lon -
g-term outcomes of endometriosis manage -
ment. Fertility and Sterility. 2024;121(1):23-
35.
Wilding JPH, Batterham RL, Calanna S, et
al. Once-weekly semaglutide in adults with
overweight or obesity. New England Journal
of Medicine. 2021;384(11):989-1002.
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Tirzepatide once weekly for the treatment of
obesity. New England Journal of Medicine.
2022;387(3):205-216.
Ferrero S, Barra F , Leone Roberti Maggiore U.
Current and emerging therapeutics for endo-
metriosis. Expert Opinion on Pharmacothera-
py. 2023;24(8):903-916.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.